Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma

Study Overview
=================
Brief Summary
-----------------
This is a national observational retrospective multi-site chart review study of patients with advanced, recurrent or metastatic endometrial carcinoma.

Official Title
-----------------
Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma: A Retrospective Study

Conditions
-----------------
Oncology, Endometrial Cancer, Advanced Cancer, Recurrent Cancer, Metastatic Cancer

Intervention / Treatment
-----------------
* Drug: Chemotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult women ≥ 18 years at index date. Documented diagnosis of advanced recurrent or metastatic endometrial cancer not eligible to primary complete surgery. Patients with interval surgery after primary CT may be eligible. Index date should represent at least the first* or second line** chemotherapy systemic treatment and occur between, 1, January 2019 and 31, December 2019. do not express refusal to her personal data processing or did not express her refusal for deceased patients. Exclusion Criteria: No clinical records for tumor imaging or administration of anti-cancer therapy. Patients with active malignancy other than EC cancer which contribute significantly to the clinical impairment of the patient during the study period, according to investigator opinion. Patients lost to follow-up, defined as patients whose last follow-up information occurs less than two years after index date (unless the patient is deceased). Patient did not receive chemotherapy systemic treatment. Patient undergo treatment by pembrolizumab or another immunotherapy in first line (cohort 1) or second line (cohort 2) during the eligibity (inclusion) period.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cohort 1<br>Patients in first line treatment (first chemotherapy for advanced, recurrent or metastatic endometrial cancer) in 2019 | Drug: Chemotherapy<br>* Patients with confirmed advanced, recurrent or metastatic endometrial cancer, treated by chemotherapy in real life-setting, between 1st January 2019 to 31rd December March 2019, in first or second line of chemotherapy.<br>|
| Cohort 2<br>Patients in second line treatment (after one prior systemic chemotherapy) in 2019 | Drug: Chemotherapy<br>* Patients with confirmed advanced, recurrent or metastatic endometrial cancer, treated by chemotherapy in real life-setting, between 1st January 2019 to 31rd December March 2019, in first or second line of chemotherapy.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical, biological and treatment characteristics | Description of the data | up to 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progession Free Survival real world (rwPFS) | From the date of initiation of the treatment in the corresponding line to the date of progression or death | through study completion, an average of 1 year | 
| Overall Survival (OS) | From the date of initiation of the treatment in the corresponding line to the date of death | through study completion, an average of 1 year |